Author:
Westendorf J. J.,Ahmann G. J.,Lust J. A.,Tschumper R. C.,Greipp P. R.,Katzmann J. A.,Jelinek D. F.
Publisher
Springer Berlin Heidelberg
Reference24 articles.
1. Kawano M, Hirano T, Matsuda T, Taga T, Horii Y, Iwato K, Asaoku H, Tang B, Tanabe O, Tanaka H, Kuramoto A, Kishimoto T (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83–85
2. Zhang XG, Klein B, Bataille R (1989) Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood 74: 11–13
3. Bataille R, Jourdan M, Zhang XG, Klein B (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. Blood 84: 2008–2011
4. Mandelli F, Awisati G, Tribalto M (1992) Biology and treatment of multiple myeloma. Curr Opin Oncology 4: 73–86
5. Muraguchi A, Hirano T, Tang B, Matsuda T, Horii Y, Nakajima K, Kishimoto T (1988) The essential role of B cell stimulating factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med 167: 332–344